News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma
Photo from outsourcing-pharma.com
Jun 18, 2023, 16:32

FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma

In a post by on Linkedin, it says, “I’m excited to share that the FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma(DLBCL). Despite the progress we’ve seen in treating DLBCL, additional treatment options are critical for those who relapse or are refractory to other treatments given the aggressive nature of this disease.
Today marks another great advancement for the blood cancer community and reinforces our steadfast commitment to those living with difficult-to-treat cancers.”

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Source:

Alexander Hardy antibody blood cancer DLBCL lymphoma
Special Coverage
Insight
Nov 30, 2024, 19:38
Stephen V Liu: Is there value in continuing osimertinib beyond progression?
Blog
Nov 30, 2024, 19:34
Secretary Xavier Becerra's Tribal Advisory Committee meeting
Blog
Nov 30, 2024, 19:29
Luca Arecco: 2nd version of the ESMO Essentials for Clinicians - Breast Cancer
Blog
Nov 30, 2024, 19:21
Lung Cancer Cohort Consortium - IARC
Blog
Nov 30, 2024, 19:17
Key takeaways from EMBARK by Bertrand Tombal
Insight
Nov 30, 2024, 19:13
Vivek Subbiah: ADC Target Expression and Interstitial Lung Disease in NSCLC
Blog
Nov 30, 2024, 19:08
6th EORTC Quality of Life in Cancer Clinical Trials Conference
Opinion
Nov 30, 2024, 18:59
Paulo G Bergerot: How exercise nutrition and psychosocial support improve outcomes in Cancer care
Blog
Nov 30, 2024, 18:55
Lisa A. Lacasse: Grateful for the Family, Volunteers, and ACS CAN's Impactful Work
Blog
Nov 30, 2024, 18:50
Francisco J. Esteva: How the MammaPrint test could identify patients who benefit from varying durations of EET
Insight
Nov 30, 2024, 18:43
A Proud Moment for Nigeria - The Dorcas Cancer Foundation
Blog
Nov 30, 2024, 18:34
Razelle Kurzrock: DART hits the target again